Genmab A/S (GMAB) stock falls on Q1 2026 Earnings

Genmab A/S (GMAB) reported first-quarter 2026 results showing solid revenue growth alongside steep declines in earnings and EPS.

Total revenue: $896 million (+25.31% year-over-year).

Gross profit: $896 million (+33.14% year-over-year).

Operating profit: $180 million (-4.26% year-over-year).

Net income attributable to common shareholders: $53 million (-72.82% year-over-year).

Diluted EPS: $0.08 (-97.26% year-over-year).

Liquidity and cash-flow details highlight a mixed picture: cash on hand rose while operating cash generation plunged.

Cash and cash equivalents: $1.7 billion (+32.33% year-over-year).

Cash from operating activities: $3 million (-98.28% year-over-year).

Purchases of property, plant and equipment: -$5 million (-54.55% year-over-year).

Cost of sales: $81 million (+92.86% year-over-year).

Total liabilities: $5.3 billion (+355.77% year-over-year).

Market reaction: shares were down 2.52% since market open this morning.

Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.

Genmab A/S Hedge Fund Activity

We have seen 156 institutional investors add shares of Genmab A/S stock to their portfolio, and 127 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

ORBIS ALLAN GRAY LTD added 3,340,456 shares (+30.2%) to their portfolio in Q4 2025, for an estimated $102,886,044
PARADIGM BIOCAPITAL ADVISORS LP added 3,222,983 shares (+84.4%) to their portfolio in Q4 2025, for an estimated $99,267,876
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP added 1,334,919 shares (+36.6%) to their portfolio in Q4 2025, for an estimated $41,115,505
BLACKROCK, INC. added 1,143,375 shares (+33.1%) to their portfolio in Q4 2025, for an estimated $35,215,950
TWO SIGMA ADVISERS, LP removed 1,092,800 shares (-76.3%) from their portfolio in Q4 2025, for an estimated $33,658,240
RENAISSANCE TECHNOLOGIES LLC added 671,307 shares (+23.8%) to their portfolio in Q4 2025, for an estimated $20,676,255
SUSQUEHANNA INTERNATIONAL GROUP, LLP added 594,371 shares (+3310.9%) to their portfolio in Q4 2025, for an estimated $18,306,626

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

Genmab A/S Analyst Ratings

Wall Street analysts have issued reports on $GMAB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

HC Wainwright & Co. issued a "Buy" rating on 02/18/2026

To track analyst ratings and price targets for Genmab A/S, check out Quiver Quantitative's $GMAB forecast page.

Genmab A/S Price Targets

Multiple analysts have issued price targets for $GMAB recently. We have seen 6 analysts offer price targets for $GMAB in the last 6 months, with a median target of $39.0.

Here are some recent targets:

Raghuram Selvaraju from HC Wainwright & Co. set a target price of $38.0 on 04/30/2026
Kalpit Patel from Wolfe Research set a target price of $32.0 on 03/27/2026
Eva Fortea Verdejo from Wells Fargo set a target price of $40.0 on 03/02/2026
Michael Schmidt from Guggenheim set a target price of $40.0 on 02/23/2026
Benjamin Jackson from Jefferies set a target price of $41.5 on 02/17/2026
Judah Frommer from Morgan Stanley set a target price of $34.0 on 02/16/2026